Drug Profile

FPF 1070

Alternative Names: Cerebrolysin

Latest Information Update: 25 Dec 2023

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Ebewe Neuro Pharma
Developer EVER Neuro Pharma
Class Nootropics; Peptides; Tissue extracts
Mechanism of Action Neuron stimulants

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Marketed Alzheimer's disease; Ischaemic stroke
Phase II CADASIL
Discontinued Brain injuries

Most Recent Events

29 Nov 2023 Phase-II clinical trials in CADASIL in Czech Republic (unspecified route) (NCT05755997) (EudraC2022-002394-29)
28 Jul 2022 Ever Neuro Pharma terminates a phase II IMPULSE trial in Ischaemic stroke in Austria due to strategic and pandemic reasons (NCT04124367)
25 Jun 2021 Ever Neuro Pharma initiates a phase II IMPULSE trial for Ischaemic stroke in Austria (NCT04124367)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com